You are here

Article Text

Article menu
Download PDFPDF
Correspondence
COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine
  1. Cheng Lay Teh1,
  2. Yaw Kiet Cheong1,
  3. Wan Rosmaiza Wan Musa2,
  4. Sharifah Aishah Wan Mohd Akbar1,
  5. Noraini Mat Husin3,
  6. Suk Chyn Gun4
  1. 1 Department of Medicine, Sarawak General Hospital, Kuching, Sarawak, Malaysia
  2. 2 Department of Medicine, Hospital Putrajaya, Putrajaya, Malaysia
  3. 3 Department of Medicine, Hospital Ipoh, Ipoh, Perak, Malaysia
  4. 4 Department of Medicine, Hospital Tuanku Ja'afar Seremban, Seremban, Negeri Sembilan, Malaysia
  1. Correspondence to Dr Cheng Lay Teh, Medicine, Sarawak General Hospital, Kuching 93450, Malaysia; tehchenglay{at}yahoo.com

https://doi.org/10.1136/annrheumdis-2020-218154

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the letter by Mathian A et al 1 describing the clinical course of COVID-19 in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. The COVID-19 Global Rheumatology Alliance registry2 shows that 19 (17%) of 110 patients with rheumatic diseases who have been diagnosed with COVID-19 as of 1 April 2020 were patients with lupus. Bozzalla Cassione et al,3 Romão et al 4 and Ye et al,5 respectively, described patients with SLE in their papers. The latest paper by D’Silva et al reported ten cases of lupus in their cohort.6 We would like to share the clinical course of COVID-19 among patients with SLE in Malaysia.

    As of 30 March 2020, there were five cases of SLE from a total of 2626 cases of COVID-19 in Malaysia. Clinical data were obtained through a review of medical records. …

    View Full Text

    Footnotes

    • Contributors CLT and SCG: study conception and design. YKC, WRWM, SAWMA and NMH: data acquisition and data analysis. CLT, YKC and SCG: manuscript preparation and critical revision. All authors read and approved the final version.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles